ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 85 of 1269 for:    depression AND Major Depression AND depressive symptoms | "Depression"

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02134808
Recruitment Status : Active, not recruiting
First Posted : May 9, 2014
Last Update Posted : December 7, 2017
Sponsor:
Information provided by (Responsible Party):
Perry Renshaw, University of Utah

Brief Summary:
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased depressive symptoms measured with the Children's Depression Rating Scale-Revised (CDRS-R) and Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with increased β-NTP concentrations.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Creatine Drug: Placebo Phase 4

Detailed Description:
The current protocol seeks to expand upon the investigators previous work by opening recruitment on a pilot study of creatine 10g daily vs. placebo as a treatment for female adolescents with SSRI-resistant MDD. The purpose of the pilot study is twofold: A) to evaluate several aspects of the feasibility of creatine supplementation as a treatment for this population; and B) to estimate the effect size of adjunctive creatine, to inform the design and implementation of a potential future efficacy trial.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study
Actual Study Start Date : March 15, 2017
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Creatine
Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
Drug: Creatine
Creatine is a nutritional supplement.
Other Name: Creatine Monohydrate

Placebo Comparator: Placebo
Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
Drug: Placebo
The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
Other Name: Placebo Control




Primary Outcome Measures :
  1. Brain phosphocreatine (PCr) concentrations [ Time Frame: 8 weeks ]
    PCr will be measured through phosphorus magnetic resonance spectroscopy (31P-MRS). This will be performed in a 3 Tesla magnetic resonance imaging (MRI) scanner.


Secondary Outcome Measures :
  1. Children's Depression Rating Scale-Revised (CDRS-R); Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 8 weeks ]
    The CDRS-R and MADRS will be administered to understand the severity of depressive symptoms, and how these symptoms change throughout the course of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

MAJOR DEPRESSIVE DISORDER SUBJECTS

Inclusion Criteria:

  1. Participants must be female.
  2. Participants must be able to grant informed consent (age >18), or parent/guardian permission plus participant assent (age <18).
  3. Participants must meet DSM criteria for Major Depressive Disorder (MDD), with current mood state depressed for > 2 weeks.
  4. Participants must be between the ages of 12 and 21.
  5. Current CDRS-R raw score of > 40 or MADRS score > 25; and CGI-S score > 3.
  6. Participants may be enrolled in individual and/or group psychotherapy, if it has been ongoing for at least 8 weeks.
  7. Participants must have been in treatment with an SSRI for at least 8 weeks, the last 4 of which were at a dosage of > 20 mg per day of fluoxetine or its equivalent, e.g. 20 mg per day of paroxetine, 20 mg citalopram, 10 mg escitalopram, or 100 mg sertraline. If the participant attempted, but could not tolerate, a dose comparable to 20 mg fluoxetine, they will be considered eligible. (This definition of "Adolescent SSRI Resistant Depression" is modified from the NIH-sponsored, $17 million TORDIA Randomized Controlled Trial [http://clinicaltrials.gov/ct2/show/NCT00018902].

Exclusion Criteria:

  1. Unstable co-morbid medical, neurological, or psychiatric disorder.
  2. Current DSM criteria for substance abuse or dependence (excepting nicotine/cigarettes).
  3. Clinically significant suicidal or homicidal risk.
  4. Pre-existing renal disease.
  5. Proteinuria on baseline urinalysis testing.
  6. Pregnancy or breastfeeding.
  7. Sexually active and unwilling to practice contraception during the study.
  8. Contraindication to magnetic resonance imaging (e.g. ferromagnetic implant or claustrophobic anxiety).
  9. History of hypersensitivity to creatine.
  10. History of a previous failed therapeutic trial of creatine.
  11. Participants may be outpatients or inpatients, but incarcerated persons will be excluded because this study is not approved for "Research Involving Prisoners."

Study Withdrawal Criteria:

  1. Withdrawal of parental permission, participant informed consent or participant assent.
  2. Onset of a psychotic disorder or bipolar disorder.
  3. Intolerable, or clinically-significant side effects to creatine.
  4. Worsening depression, as demonstrated by an increase in CDRS-R or MADRS score > 25% from baseline.
  5. Positive pregnancy test.
  6. A significant change to the participant's medication or psychotherapy treatment from the regimen reported at their baseline/screening visit (e.g. if the SSRI is discontinued).
  7. Incarceration, as the study is not approved to conduct "Research Involving Prisoners."
  8. If a clinically-significant intracranial lesion is found by the Radiologist on a participant's baseline brain scan, they will be withdrawn from the study and referred for appropriate medical care.
  9. The principal investigator retains the right to withdraw participants from the study without their permission, in the event they are unwilling or unable to maintain adherence with the research protocol.

HEALTHY COMPARISON SUBJECTS

Inclusion Criteria:

  1. Participants must be able to grant informed consent (age > 18), or parent/guardian permission plus participant assent (age < 18).
  2. Participants must be female.
  3. Participants must be between the ages of 12 and 21 years.
  4. Participants must not meet DSM criteria for a current psychiatric illness or substance use disorder.
  5. Participants must have a CDRS-R score < 30.

Exclusion Criteria:

  1. Unstable medical or neurological illness.
  2. Clinically-significant psychiatric or substance use disorder.
  3. Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus. In addition, women of childbearing potential who are unable or unwilling to practice contraception during the study will be excluded. Female participants who are of childbearing potential must have a negative urine pregnancy test before the MRI/MRS scan.
  4. Participants with a contraindication to MRI/MRS scanning, such as a metallic implant.

Study Withdrawal Criteria:

  1. Withdrawal of parental permission or participant assent.
  2. Onset of a psychotic disorder or depression.
  3. Positive pregnancy test.
  4. A significant change to the participant's medication or psychotherapy treatment from the regimen reported at their baseline/screening visit, unless directed by the principal investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02134808


Locations
United States, Utah
University of Utah School of Medicine
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
Perry Renshaw
Investigators
Study Director: Douglas Kondo, MD University of Utah
Principal Investigator: Perry F Renshaw, MD, PhD, MBA University of Utah

Publications:
Responsible Party: Perry Renshaw, Professor of Psychiatry, University of Utah
ClinicalTrials.gov Identifier: NCT02134808     History of Changes
Other Study ID Numbers: 00073442
First Posted: May 9, 2014    Key Record Dates
Last Update Posted: December 7, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Perry Renshaw, University of Utah:
Major Depressive Disorder
Creatine
Brain Chemistry
Magnetic Resonance Spectroscopy
Treatment Resistance
Selective Serotonin Reuptake Inhibitor (SSRI) Resistance

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Behavioral Symptoms
Disease
Pathologic Processes
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs